<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154476</url>
  </required_header>
  <id_info>
    <org_study_id>16-008985</org_study_id>
    <nct_id>NCT03154476</nct_id>
  </id_info>
  <brief_title>Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study</brief_title>
  <acronym>SiFALD</acronym>
  <official_title>Sildenafil for Fontan Associated Liver Disease (SiFALD) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the medication, sildenafil (also known as&#xD;
      Revatio), can slow or stop the progression of liver disease in patients who previously had a&#xD;
      Fontan operation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. All participants will undergo a baseline liver magnetic resonance elastography. The&#xD;
           patients with liver stiffness score &gt;2.5 kiloPascal (KPa) [Normal: ≤2.5 KPa] will be&#xD;
           enrolled in the study.&#xD;
&#xD;
        2. In addition to a baseline liver MRE, all participants will undergo cardiac MRI,&#xD;
           transthoracic echocardiogram (TTE), FibroSure® (alpha-2 macroglobulin, haptoglobulin,&#xD;
           gamma-glutamyltransferase, bilirubin, apolipoprotein A1, and alanine transaminase), and&#xD;
           chemistry panel.&#xD;
&#xD;
        3. This will be a double blinded placebo control study design. All participants will be&#xD;
           randomized 1:1 to sildenafil or placebo for a total of 12 months therapy.&#xD;
&#xD;
        4. Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to&#xD;
           10 mg 3 times per day for the second week and 20 mg 3 times per day from the 3rd week to&#xD;
           the end of the study period. The patients will be required to check their pulse rate and&#xD;
           blood pressure daily during the first month of drug therapy. Patient who experience&#xD;
           hypotension (blood pressure &lt; 90/50 plus symptoms such as dizziness) during dose&#xD;
           titration will be asked to remain on the previous tolerated dose. Patients who cannot&#xD;
           tolerate 10 mg 3 times daily will be asked to withdraw from the study and will be asked&#xD;
           to continue checking their blood pressure for three days after stopping the medication.&#xD;
&#xD;
        5. After 12 months (+/- 2 weeks) of therapy, all imaging studies (liver MRE, cardiac MRI,&#xD;
           TTE) and blood tests (FibroSure® and chemistry panel) will be repeated. A final liver&#xD;
           MRE and FibroSure will be performed at 18 months (+/- 2 weeks) for the participants&#xD;
           whose 18 months follow-up still falls within the study period.&#xD;
&#xD;
        6. Adverse event and compliance monitoring: During the first month of enrollment&#xD;
           (initiation and dose titration), adverse events will be collected by subject report and&#xD;
           by weekly telephone interview with dedicated research personnel. For the rest of the&#xD;
           study period, adverse events will be collected by subject report and by monthly&#xD;
           telephone interview with dedicated research personnel. The research personnel will be&#xD;
           responsible for sending out the monthly supply of medications and obtaining a count of&#xD;
           the remaining number pills as a measure of compliance. All participants will be provided&#xD;
           with a pamphlet containing all the side effects of sildenafil, and contact information&#xD;
           of research team for reporting any adverse event of concerns about the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double-blind Placebo-control study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Both the treatment arm (sildenafil) and the placebo arm will receive monthly package of similar pills. Equal number of patients will be randomly assigned to each arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE)</measure>
    <time_frame>Baseline, 12 months (52 weeks), 24 months (104 weeks)</time_frame>
    <description>Measured using magnetic resonance imaging derived liver stiffness (MRE-LS) reported in kilopascal (kPa).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo times per day for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules matching study drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  All adult Fontan patients who have no contraindications for magnetic resonance imaging&#xD;
             (MRI) will be eligible for the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subjects with implantable pacemakers&#xD;
&#xD;
          -  Residual cardiac lesions (severe ventricular dysfunction, severe atrioventricular&#xD;
             valve regurgitation, Fontan baffle or conduit obstruction)&#xD;
&#xD;
          -  Viral hepatitis&#xD;
&#xD;
          -  Severe renal dysfunction&#xD;
&#xD;
          -  History of sildenafil use in the six months prior to study enrollment&#xD;
&#xD;
          -  Ongoing sildenafil therapy&#xD;
&#xD;
          -  Patients currently taking nitrates&#xD;
&#xD;
          -  Hypotension at baseline (BP &lt;90/50 mmHg)&#xD;
&#xD;
          -  Pulmonary veno-occlusive disease&#xD;
&#xD;
          -  Hearing/vision impairment&#xD;
&#xD;
          -  Pulmonary hypertension due to sickle cell disease&#xD;
&#xD;
          -  Women of child-bearing potential with a positive pregnancy test will additionally be&#xD;
             excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander C Egbe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <results_first_submitted>July 7, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Alexander C. Egbe</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The safety of the subject will be monitored throughout the duration of the study. During the first month of enrollment (initiation and dose titration), adverse events will be collected by subject report and by weekly telephone interview with dedicated research personnel. For the rest of the study period, adverse events will be collected by subject report and by monthly telephone interview with dedicated research personnel. All participants will be provided with a pamphlet containing all the side effects of sildenafil, and contact information of research team for reporting any adverse event of concerns about the study.&#xD;
The patients will be required to check their pulse rate and blood pressure daily during the first month of drug therapy. Patient who experience hypotension (blood pressure &lt; 90/60 plus symptoms such as dizziness) during dose titration will be asked to remain on the previous tolerated dose</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03154476/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil</title>
          <description>Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.&#xD;
Sildenafil: Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will receive placebo times per day for 12 months.&#xD;
Placebo: Placebo capsules matching study drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil</title>
          <description>Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.&#xD;
Sildenafil: Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects will receive placebo times per day for 12 months.&#xD;
Placebo: Placebo capsules matching study drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="6"/>
                    <measurement group_id="B2" value="29" spread="5"/>
                    <measurement group_id="B3" value="29" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE)</title>
        <description>Measured using magnetic resonance imaging derived liver stiffness (MRE-LS) reported in kilopascal (kPa).</description>
        <time_frame>Baseline, 12 months (52 weeks), 24 months (104 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.&#xD;
Sildenafil: Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive placebo times per day for 12 months.&#xD;
Placebo: Placebo capsules matching study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE)</title>
          <description>Measured using magnetic resonance imaging derived liver stiffness (MRE-LS) reported in kilopascal (kPa).</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" spread="0.73"/>
                    <measurement group_id="O2" value="5.72" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.94"/>
                    <measurement group_id="O2" value="5.68" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="0.86"/>
                    <measurement group_id="O2" value="5.74" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline to end of study for a total of approximately 24 months on all participants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil</title>
          <description>Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.&#xD;
Sildenafil: Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will receive placebo times per day for 12 months.&#xD;
Placebo: Placebo capsules matching study drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexander Egbe</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3725</phone>
      <email>Egbe.Alexander@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

